A patient case of a 50-year-old man with hormone-sensitive prostate cancer sparked a debate among oncologists regarding the best course of action.
David Morris, MD, MS
Advertisement
Articles by David Morris, MD, MS
A patient case of a 50-year-old man with hormone-sensitive prostate cancer sparked a debate among oncologists regarding the best course of action.
The Oncology Decoded podcast highlighted the impact of the results from the NIAGARA trial for patients with bladder cancer in a post-ASCO GU discussion.
The Oncology Decoded podcast highlighted the impact of the results from the NIAGARA trial for patients with bladder cancer in a post-ASCO GU discussion.
Advertisement
Latest Updated Articles
Navigating Treatment Intensification in Metastatic Hormone-Sensitive Prostate CancerPublished: March 5th 2025 | Updated:
Episode 1: NIAGARA Study is the Forefront of Post-ASCO GU Discussion in Bladder CancerPublished: March 4th 2025 | Updated:
- Episode 2: Navigating Treatment Intensification in Metastatic Hormone-Sensitive Prostate Cancer
Published: March 5th 2025 | Updated:
- NIAGARA Study is the Forefront of Post-ASCO GU Discussion in Bladder Cancer
Published: March 4th 2025 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
ESMO 2025: The Top 10 Takeaways That May Shift Oncology Practice
2
FDA Approves Revumenib in R/R NPM1-Mutant AML
3
Awareness Fuels Progress: Upcoming Advances in Breast Cancer Treatment
4
FDA Approves Belantamab Mafodotin in R/R Multiple Myeloma
5
